AstraZeneca PLC (LON:AZN - Get Free Report) insider Aradhana Sarin sold 9,563 shares of AstraZeneca stock in a transaction on Thursday, August 14th. The shares were sold at an average price of £115.12 ($156.12), for a total value of £1,100,892.56 ($1,492,938.11).
AstraZeneca Stock Up 1.3%
Shares of AstraZeneca stock traded up GBX 146 ($1.98) during trading on Monday, hitting £117.38 ($159.18). 1,422,503 shares of the stock were exchanged, compared to its average volume of 10,569,400. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. The firm's 50-day moving average price is £107.04 and its 200 day moving average price is £108.90. The stock has a market cap of £225.84 billion, a price-to-earnings ratio of 32.17, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. AstraZeneca PLC has a 12-month low of GBX 9,573.51 ($129.83) and a 12-month high of £133.88 ($181.56).
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and set a £110 ($149.17) target price on shares of AstraZeneca in a report on Wednesday, July 30th. Shore Capital reissued a "buy" rating and set a £135 ($183.08) target price on shares of AstraZeneca in a research note on Tuesday, July 29th. Finally, Berenberg Bank reaffirmed a "buy" rating and issued a GBX 140 ($1.90) price target on shares of AstraZeneca in a research report on Friday, May 16th.
View Our Latest Stock Report on AZN
AstraZeneca Company Profile
(
Get Free Report)
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access